Russian Gliptin is Globally Recognized
Russian single use gliptin for treatment of type 2 diabetes (T2DM) has been approved. The news has been announced at the Biotechnology Forum BIO International Convention, San Francisco.
Saterex a company of High-technology center ChemRar has developed an innovative sugar lowering drug (INN Gosogliptin). The new drug is the first Russian single use gliptin for monotherapy or combination therapy with metformin in type 2 diabetes mellitus (T2DM). It will be manufactured in Russia for full manufacturing cycle, including substance synthesis.
The new drug (trade name SaterexÒ) is a DPP-IV inhibitor which lowers blood glucose level by normalizing so-called incretin effect usually lowered in T2DM patients.
Drug study program began in 2012. Its safety and efficacy was proved in the four years, and this may it was registered in the territory of the Russian Federation.
The project was implemented under support of the Ministry of Industry and Trade of the Russian Federation within the framework of the Federal Target Program Pharma 2020.